Gilead Lures Roche Pharma CEO O'Day As CEO; Genentech's CEO Will Replace Him
O'Day brings Gilead experience in oncology and M&A from a large, diversified organization.
You may also be interested in...
After several staff departures, Gilead consolidates its research arm under CEO oversight, while welcoming another Roche/Genentech alum.
In a time of internal transition, Roche emphasized its deep roots and broad pipeline at its annual event alongside the American Society for Clinical Oncology meeting.
On his first earnings call, the new CEO said he wanted to make a quick decision on Kite, which will have its own CEO and autonomy. The unit's Yescarta posted 19% sequential revenue growth.